ArticleFrontiers in immunology2023

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.

Zhiyu Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.